6533b820fe1ef96bd1279a13
RESEARCH PRODUCT
Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group
Jose A. RocaMaria H. BerrocalRoberto Gallego-pinazoLuiz H. LimaSergio RojasJ. Fernando ArevaloMartin SerranoFrancisco RodríguezDavid Lozano-rechyJay ChhablaniJans Fromow-guerraLihteh Wusubject
Laser surgeryMaleFluorescein angiographyretinaVisual acuityoptical coherencegenetic structuresPhysiologymedicine.medical_treatmentCentral serous chorioretinopathyVisual AcuityPhotodynamic therapytreatment lasersProceduresPhotodynamic therapychemistry.chemical_compound0302 clinical medicineBest corrected visual acuityMedicineFluorescein AngiographyTreatment outcomeMiddle agedTomographyPriority journalLow level laser therapyPhotosensitizing Agentsmedicine.diagnostic_testMiddle AgedFluorescein angiographyVerteporfinPhotosensitizing agentsSensory SystemsIndocyanine greenMulticenter studyBevacizumabClinical trialRetrospective studyTreatment OutcomeCentral Serous ChorioretinopathyFemaleLaser Therapymedicine.symptomTomography Optical Coherencemedicine.drugHumanIndocyanine GreenAdultmedicine.medical_specialtyVisual acuityLaser surgeryMajor clinical studyFollow-up studiesPathophysiologyArticleChronic disease03 medical and health sciencesCellular and Molecular NeuroscienceLaser therapyOphthalmologyFluorescence angiographyHumansmaculaLow level laser therapyRetrospective StudiesDisease durationPhotosensitizing agentOptical coherence tomographybusiness.industryIntermethod comparisonSubretinal neovascularizationCentral serous retinopathyVerteporfinFollow upmedicine.diseaseMulticenter study (topic)eye diseasesRetrospective studiesOphthalmologyCentral serous retinopathychemistryPhotochemotherapyChronic Disease030221 ophthalmology & optometryYellow micropulse laserComparative studysense organsbusinessIndocyanine greenControlled study030217 neurology & neurosurgeryFollow-Up Studiesdescription
PurposeTo compare the functional and anatomical outcomes of eyes with chronic central serous chorioretinopathy treated with yellow micropulse (MP) laser versus half-dose verteporfin photodynamic therapy (PDT).MethodsThis is a multicentre, retrospective comparative study of 92 eyes treated with yellow MP laser (duty cycle of 5%, zero spacing between spots, spot size varied from 100 to 200 µm, power varied from 320 to 660 mW, and the pulse burst duration was 200 ms) and 67 eyes treated with PDT (half-dose verteporfin (3 mg/m2) infused over 10 min), followed by laser activation for 83 s. Spot sizes varied from 400 to 2000 µm.ResultsIn the MP group, at 12 months of follow-up, the mean best corrected visual acuity (BCVA) improved from the logarithm of the minimum angle of resolution (logMAR) of 0.41±0.27 at baseline to 0.21±0.26 (P<0.0001), 48.9% (45/92) of eyes had an improvement of ≥3 lines of BCVA from baseline, 48.9% (45/92) of eyes remained within 2 lines of baseline BCVA, and only 2.2% (2/92) of eyes lost ≥3 lines of BCVA from baseline. In the PDT group, at 12 months of follow-up, the mean BCVA changed from logMAR of 0.50±0.34 at baseline to 0.47±0.34 (P=0.89), 19% (13/67) of eyes had an improvement of ≥3 lines of BCVA from baseline, 73% (49/67) of eyes remained within 2 lines of baseline BCVA, and 7% (5/67) of eyes lost ≥3 lines of BCVA from baseline. There were no adverse events attributable to the yellow MP laser treatment. One eye in the PDT group developed choroidal neovascularisation, which was treated with three intravitreal bevacizumab injections.ConclusionsBoth PDT and MP are effective in restoring the macular anatomy. In places where PDT is not available, yellow MP laser may be an adequate treatment alternative.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-01-01 |